Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > AME study results

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Aug 03, 2021 9:22am

194 Views

Post# 33641601

RE:RE:AME study results

YYou get that just b/c the AME study had an issue doesn't necessarily correlate to your post / theory on 13 July which would have been only two or so weeks into the trial (PH2 was 2 weeks)... let alone you were implying the price decline (which shockingly has been correlated to the XBI) that was occuring days and weeks before the AME trial started. all patients of the 42 had been dosed for a min of 21 days.. Again your post was on 13 July less than two weeks into the trial...

<< Previous

Bullboard Posts

Next >>

Dynamic Funds Launches new ETF series on the TSX